Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
50.11
-1.64 (-3.16%)
Mar 31, 2025, 1:15 PM EDT - Market open
Tarsus Pharmaceuticals Revenue
In the year 2024, Tarsus Pharmaceuticals had annual revenue of $182.95M with 948.62% growth. Tarsus Pharmaceuticals had revenue of $66.41M in the quarter ending December 31, 2024, with 407.86% growth.
Revenue (ttm)
$182.95M
Revenue Growth
+948.62%
P/S Ratio
10.63
Revenue / Employee
$566,418
Employees
323
Market Cap
1.92B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TARS News
- 18 days ago - Tarsus Announces Pricing of Upsized $125.0 Million Public Offering - GlobeNewsWire
- 18 days ago - Tarsus Announces Proposed $100.0 Million Public Offering - GlobeNewsWire
- 20 days ago - Tarsus Pharma: Strong Execution In Xdemvy Commercialization - Seeking Alpha
- 24 days ago - Tarsus to Participate in Upcoming Investor Conference - GlobeNewsWire
- 4 weeks ago - Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 - GlobeNewsWire
- 2 months ago - Tarsus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care - GlobeNewsWire